Articles tagged with Inhibitory Effects
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A comparative effectiveness study found that SGLT2 inhibitors were associated with a lower risk of chronic kidney disease and acute kidney injury compared to GLP-1 receptor agonists. These findings suggest that SGLT2 inhibitor treatment may be an effective strategy for preventing kidney disease in individuals with type 2 diabetes.
The study found clear absolute benefits of SGLT2 inhibitors on kidney, hospitalization, and mortality outcomes regardless of diabetes status and level of urine albumin to creatinine ratio. This benefit suggests a potential therapeutic approach for patients with kidney disease.
The study suggests that SGLT2 inhibitors can benefit patients with varying levels of kidney function and albuminuria. Routine use of these medications may lead to improved kidney outcomes across different patient groups.
A recent study published in JAMA Network Open found that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment was associated with reduced all-cause mortality among older patients with cancer and type 2 diabetes. The survival benefit persisted across various subgroups, including age, sex, and cancer type.
Researchers find inhibiting TMEM219 signaling restores mucosal healing in inflammatory bowel diseases and protects intestinal stem cells from death. The study suggests TMEM219 overactivation induces intestinal stem cell death, preventing mucosal renewal during inflammation.
Indigenous Nigerian food plants, such as Spondias mombin and Xanthosoma sagittifolium, contain flavonoids, alkaloids, terpenoids, and phenolic acids that exhibit anticancer properties. These plants induce apoptosis, inhibit cell proliferation, reduce oxidative stress, and modulate key cellular pathways.
A clinical trial found that LUT014, a topical BRAF inhibitor, significantly reduced the severity of acne-like skin rashes caused by targeted therapy for colorectal cancer. Patients who received LUT014 had improved quality of life and were able to continue receiving their cancer treatment with reduced side effects.
A Phase II trial found durable antitumor activity in patients with BRCA1/2 mutations treated with olaparib and pembrolizumab, with 8.3% complete response rate
Researchers from the University of Cincinnati Cancer Center presented abstracts highlighting contrasting effects of a protein on head and neck, breast, and lung cancers. The study found increased levels of IL-9 in patients with head and neck cancer correlated with decreased survival, while elevated IL-9 was associated with smaller tumo...
A new study at Stellenbosch University found that blocking the enzymes involved in glycolysis could cut off the malaria parasite's primary energy source and kill it. This approach has shown promise for developing new malaria drugs, particularly against resistant parasites.
Researchers at Texas Tech University Health Sciences Center have received a $1.94 million grant to study inhibitors that target peripheral neuropathic pain. The project aims to develop novel non-opioid and non-addicting therapies capable of effectively managing chronic pain.
Common prescription medications can disrupt sterol biosynthesis, potentially causing developmental disorders. The editorial highlights the need for mandatory sterol biosynthesis screening in clinical practice.
A study by Johns Hopkins Medicine found that older adults with cancer benefit equally from immunotherapy treatments as younger patients, with key differences in their immune responses and cells. Researchers hope to develop new therapies tailored to different age groups' needs and improve treatment success.
Researchers at Penn's School of Dental Medicine and Perelman School of Medicine found that ACE inhibitors can inhibit the activity of ACE2, a critical cardioprotective enzyme. This discovery has implications for human patients prescribed these medications, who may benefit from additional ACE2 treatment.
A novel compound ML233 inhibits melanin production with no significant toxic side effects, offering a potential new strategy for treating pigment-related skin conditions. The study demonstrates promising results in reducing melanin synthesis and proliferation of melanoma cells.
Researchers at St. Jude Children's Research Hospital have designed a new drug framework that selectively targets the CYP3A4 enzyme, reducing off-target effects. The discovery provides a roadmap for future drug developers to better evaluate drug interactions and selectively target CYP proteins.
Researchers discovered TBX2 drives therapy resistance by shifting signaling from the androgen receptor to the glucocorticoid receptor. The study identified a strategy to target this switch, potentially predicting patient risk and offering new treatment approaches.
Combining PCSK9 inhibitors with anti-PD-1/PD-L1 treatment may improve antitumor effects. PCSK9 inhibition enhances antigen presentation, promoting T cell recognition and killing of tumor cells.
Scientists from the University of Zurich created decoy molecules that bind to autoantibodies, preventing them from inhibiting type I interferons. This restoration restores antiviral effect on viruses like influenza, offering hope for treatment and reducing viral disease susceptibility.
Research suggests flavonoids improve insulin sensitivity, enhance β-cell function, modulate the gut microbiota, inhibit gluconeogenesis, and regulate enteroendocrine hormones in type 2 diabetes management. Flavonoid-specific effects on GLP-1, GIP, PYY, and CCK secretion contribute to improved glycemic control.
New guidelines support safe and efficient use of JAK inhibitors for treating chronic inflammatory diseases like rheumatoid arthritis, psoriasis, and Crohn's disease. The updated consensus statement considers safety concerns, including cardiovascular disease and cancer risk, to ensure individualized treatment decisions.
Researchers found that semisynthetic bile acid NorUDCA inhibits pro-inflammatory T helper 17 cells and promotes anti-inflammatory regulatory T cells in the intestine. This could lead to new therapies for inflammatory bowel diseases such as ulcerative colitis or Crohn's disease.
PARP inhibitors have been found to be effective in treating cancers with BRCA1/2 mutations by blocking DNA repair pathways. The combination of PARPis with chemotherapeutic drugs can also improve treatment efficacy, increasing DNA damage and blocking repair processes.
Researchers at University of Arizona Cancer Center found that an immunotherapy previously shown to be ineffective against prostate cancer may have therapeutic potential when combined with a specific protein inhibitor. The study's co-author, Noel Warfel, PhD, identified a way to sensitize prostate tumors to immune checkpoint inhibitors ...
This study investigates coumarin derivatives as MAO inhibitors, revealing phenyl substitution's impact on inhibitory activity and selectivity. The findings provide new insights into the interactions between coumarins and MAOs, contributing to the development of coumarin-based MAO inhibitors.
Researchers found that olpasiran significantly lowers lipoprotein(a) levels by over 95% and reduces oxidized phospholipids, which promote atherosclerosis. The study also showed no significant effects on inflammatory markers.
Researchers at Ben-Gurion University found that chronic stress changes how the brain processes sounds, with higher decibel levels needed to trigger similar responses. This effect may be driven by a type of inhibitory cell becoming more active under repeated stress.
Researchers at Osaka Metropolitan University assessed target genes in canine hepatocellular carcinoma (HCC) to develop molecular targeted therapies. The study identified potential gene targets, including PDGFB, which may improve treatment options for unresectable HCC.
Researchers at MD Anderson Cancer Center have made significant advancements in treating oligometastatic prostate cancer, advanced urothelial cancer, and triple-negative breast cancer. Personalized risk-based screening is also being explored as a tool to reduce cancer deaths.
Researchers identified S6K2 as a potential target for treating NRAS MUT melanoma, which accounts for 30% of all melanoma cases. The team found that silencing S6K2 killed cancer cells by disrupting lipid metabolism, and combining treatment with two compounds improved therapeutic outcomes.
Researchers at Weill Cornell Medicine have identified a specific brain circuit that appears to reduce anxiety without side effects. The study suggests a new target for treating anxiety disorders and demonstrates a general strategy for mapping drug effects on the brain.
A new compound, V-161, has been discovered to effectively inhibit the growth of vancomycin-resistant Enterococci (VRE) by targeting a crucial enzyme. The study reveals that V-161 not only disrupts the enzyme function but also reduces VRE colonization in the mouse small intestine.
Researchers analyzed 101 Chinese AML samples and identified three subtypes with different molecular characteristics and clinical outcomes. The study also found potential drug combinations that could improve treatment efficacy for subtype S-II&III patients who benefited from allogenic haematopoietic stem cell transplantation.
Researchers have identified a key protein called Apex1 as a potential therapeutic target for stopping the immune system from attacking itself. By inhibiting this protein, harmful T cells that cause autoimmune diseases and allergies can be eliminated.
Researchers designed metallo-supramolecular complexes that selectively bind to MPXV mRNA G4, modulating A5L protein expression and immune response activation. These findings highlight the significance of G4s in viral immunodominant protein expression and offer potential avenues for developing antiviral therapeutics.
Researchers developed a novel inhalable therapeutic delivery system for lung cancer using mucoadhesive protein nanoparticles inspired by marine mussels. The approach leverages the adhesive properties of mussel proteins to enable selective payload release and minimize adverse effects.
A new study reveals multilingualism enhances executive function skills, including focus, understanding perspectives, communication, and reduces repetitive behaviors in both autistic and non-autistic children. Parents of multilingual households report stronger overall executive function compared to mono-lingual households.
A study investigated the effects of N-(1,3,4-thiadiazol-2-yl)-3-pyridinecarboxamide (TGN-020), a selective AQP4 inhibitor, on glymphatic function. The results showed that acute inhibition of AQP4 significantly impaired glymphatic function without inducing short-term behavioral abnormalities in mice.
A study by MedUni Vienna identified a promising therapeutic approach for metabolic liver diseases by targeting fat metabolism inhibition, promoting liver health and reducing liver fat, inflammation and fibrotic remodeling. The approach involves blocking ATGL, an enzyme playing a central role in lipid metabolism.
A new Northwestern Medicine study reveals how metformin lowers glucose levels by targeting mitochondrial complex I in cells. The drug also improves COVID outcomes and reduces inflammation, suggesting that mitochondrial complex I inhibition may be a unifying mechanism behind its diverse effects.
Researchers found that EZH2 inhibition boosts T-cell immunotherapies' effectiveness by making cancer cells more visible and reducing immunosuppressive regulatory T-cells. This combination therapy showed improved survival rates in mice with lymphomas, suggesting a potential new approach to treating certain cancers.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
A new study by Weill Cornell Medicine scientists reveals that the enzyme EZH2 drives aggressive tumor growth in treatment-resistant prostate cancers. The absence of protein PKCλ/ι enables EZH2's alternative function, promoting cancer progression despite androgen receptor inhibitors.
A new oral medication, muvalaplin, has shown promising results in lowering lipoprotein(a) levels, a marker of cardiovascular risk. The study's findings suggest that muvalaplin may be a valuable treatment option for individuals with high lipoprotein(a) levels.
A clinical study found that an FasL inhibitor, asunercept, led to a faster recovery of COVID-19 patients in eight days compared to 13 days in the control group. The treatment also reduced mortality by about 20%. The study suggests a new therapeutic concept for severe COVID-19.
Researchers at UC Riverside develop a novel method to degrade the Pin1 protein, which is involved in pancreatic cancer development. The 'molecular crowbar' strategy has the potential to target and break down harmful proteins, offering new hope for cancer therapy.
A new study introduces a multi-omics-based molecular classification of gastrointestinal stromal tumors, categorizing them into four distinct subtypes. The findings identify key genetic signatures and tumor suppressor genes that influence treatment response, providing a roadmap for personalized therapy strategies.
Researchers at Tel Aviv University have discovered a new cancer mechanism that prevents the immune system from attacking tumors. The discovery was made by reversing this mechanism, which stimulates the immune system to fight cancer cells, including those resistant to prevailing forms of immunotherapy.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers at MIT have discovered additional brain pathways that modulate dopamine release, influencing movement and emotional decisions. The newly identified pathways appear to relay emotional information that helps shape motivation to take action.
Scientists have discovered a natural compound called sulfuretin that can halt the progression of certain forms of cancer and demyelinating conditions like multiple sclerosis. The study found that sulfuretin blocks the activity of an enzyme involved in these diseases, suggesting its potential as a treatment.
Researchers found that WNTinib significantly delayed tumour growth and extended survival in mice with hepatoblastoma cells harboring CTNNB1 mutations. The treatment also showed promise in shrinking tumors in patients' tumor tissue models, with some tumors disappearing completely.
Researchers found that female mouse models of Rett syndrome have a mosaic-like distribution of cells expressing wild-type and mutant MeCP2 protein, leading to dysregulated genes. The study also discovered an unusual disease progression, with females having more dysregulated genes at the pre-symptomatic stage than later on.
Researchers at Weill Cornell Medicine have developed a virtual screening approach to identify small molecule drug candidates targeting cancer checkpoints. The method successfully identified two compounds with potential therapeutic activity against TIM-3 and VISTA inhibitory checkpoints.
A study by Johns Hopkins Medicine found distinct immune 'signatures' in patients who developed adverse events while taking immunotherapy. These signatures, including increases in white blood cells known as Th2 and Th17, predict the development of immune-related adverse events and may be targeted for treatment.
A study from Goethe University Frankfurt reveals that venomous crustaceans, specifically remipede crabs in Mexican cenote caves, contain a variety of toxins with pharmacological potential. The xibalbines peptides effectively inhibit potassium channels and activate signaling pathways involved in pain sensitization.
Researchers found that zinc supplements can inhibit the transfer of AMR plasmids, reducing the spread of antibiotic-resistant infections. The study provides hope for developing an inexpensive and effective method to combat the growing threat of antimicrobial resistance.
Researchers at University of Gothenburg propose inhibiting somatostatin to restore glucagon release and prevent dangerous blood sugar levels. This approach has the potential to save lives and is supported by experimental results in mice with type 1 diabetes.
A phase 1b/2 clinical trial found a combination of immunotherapy and FGFR inhibitor to be safe and tolerable in patients with locally advanced or metastatic bladder cancer. The treatment showed increased response rates, including 54% for patients with high FGFR mRNA expression.
New study finds that extended estrogen suppression using aromatase inhibitors for hormone receptor-positive postmenopausal breast cancer is safe and does not increase the risk of coronary artery calcification. The duration of treatment and presence of osteoporosis were not associated with increased coronary artery calcification scores.